MA54904A - Compositions pharmaceutiques comprenant du méloxicam - Google Patents

Compositions pharmaceutiques comprenant du méloxicam

Info

Publication number
MA54904A
MA54904A MA054904A MA54904A MA54904A MA 54904 A MA54904 A MA 54904A MA 054904 A MA054904 A MA 054904A MA 54904 A MA54904 A MA 54904A MA 54904 A MA54904 A MA 54904A
Authority
MA
Morocco
Prior art keywords
meloxicam
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
MA054904A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MA54904A publication Critical patent/MA54904A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
MA054904A 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du méloxicam MA54904A (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US201962955905P 2019-12-31 2019-12-31

Publications (1)

Publication Number Publication Date
MA54904A true MA54904A (fr) 2021-12-15

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054904A MA54904A (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du méloxicam

Country Status (17)

Country Link
EP (1) EP3920909A4 (fr)
JP (3) JP7237386B2 (fr)
KR (1) KR20210118880A (fr)
CN (1) CN113423397A (fr)
AU (2) AU2020218253B2 (fr)
BR (1) BR112021015467A2 (fr)
CA (2) CA3213549A1 (fr)
CL (1) CL2021002070A1 (fr)
CO (1) CO2021010380A2 (fr)
CR (1) CR20210420A (fr)
EC (1) ECSP21060962A (fr)
IL (1) IL285389A (fr)
MA (1) MA54904A (fr)
MX (1) MX2021009435A (fr)
PE (1) PE20212157A1 (fr)
SG (1) SG11202107926XA (fr)
WO (1) WO2020163620A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230125826A (ko) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126841B1 (fr) 1998-11-02 2004-12-15 Merck & Co., Inc. Combinaisons d'une agoniste 5ht1b/1d et d'un inhibiteur selective de cox-2 destinees au traitement de migraine
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SG11201706123XA (en) * 2015-02-10 2017-08-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
SI3256138T1 (sl) 2015-11-25 2022-07-29 Axsome Therapeutics, Inc. Farmacevtski sestavki, ki obsegajo meloksikam
KR20190066607A (ko) * 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CA3121746A1 (en) 2017-01-04 2018-07-12 Herriot TABUTEAU Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN116999563A (zh) 2017-05-10 2023-11-07 艾克萨姆治疗公司 包含美洛昔康的药物组合物

Also Published As

Publication number Publication date
PE20212157A1 (es) 2021-11-09
CR20210420A (es) 2021-12-22
JP7237386B2 (ja) 2023-03-13
MX2021009435A (es) 2021-09-10
JP2023062144A (ja) 2023-05-02
AU2020218253A1 (en) 2021-08-12
CN113423397A (zh) 2021-09-21
CA3128940C (fr) 2023-11-07
CL2021002070A1 (es) 2022-04-01
AU2020218253B2 (en) 2023-02-23
WO2020163620A1 (fr) 2020-08-13
CA3128940A1 (fr) 2020-08-13
ECSP21060962A (es) 2021-11-30
BR112021015467A2 (pt) 2021-10-05
JP2024026732A (ja) 2024-02-28
KR20210118880A (ko) 2021-10-01
JP7420990B2 (ja) 2024-01-23
JP2022519670A (ja) 2022-03-24
AU2023202545A1 (en) 2023-05-18
SG11202107926XA (en) 2021-08-30
CO2021010380A2 (es) 2021-09-30
IL285389A (en) 2021-09-30
CA3213549A1 (fr) 2020-08-13
EP3920909A4 (fr) 2022-11-30
EP3920909A1 (fr) 2021-12-15

Similar Documents

Publication Publication Date Title
MA55206A (fr) Polyribonucléotides circulaires et compositions pharmaceutiques associées
MA52421A (fr) Composés pharmaceutiques
IL279442A (en) Pharmaceutical preparations that include meloxicam
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
EP3621621A4 (fr) Compositions pharmaceutiques contenant du méloxicam
MA50541A (fr) Formulations pharmaceutiques
MA55015A (fr) Formulations pharmaceutiques
MA43402A (fr) Composition pharmaceutique comprenant un inhibiteur puissant d'urat1
MA46867A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
DK3661373T3 (da) Farmaceutisk sammensætning mod anæmi
MA49837A (fr) Compositions pharmaceutiques
MA49977A (fr) Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
MA44079A (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA47516A (fr) Composition pharmaceutique
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA52704A (fr) Préparation pharmaceutique
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
DK3601277T3 (da) Farmaceutisk formulering
DK4058148T3 (da) Doseringsregime for anti-bcma-midler
MA54904A (fr) Compositions pharmaceutiques comprenant du méloxicam
MA54095A (fr) Formulations pharmaceutiques aqueuses
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
MA53099A (fr) Formes d'ivosidénib et compositions pharmaceutiques